Amarin: VAZKEPA® (Icosapent Ethyl) Approved by Israel's Ministry of Health

  Approval of VAZKEPA® to Reduce the Risk of Cardiovascular (CV) Events in Adult Statin-Treated Patients at High CV Risk with Elevated Triglycerides and Other High-Risk Characteristics as Studied in REDUCE-IT –-

-- Heart Disease Second Leading Cause of Death in Men and Women Aged 45 and Older in Israel --

https://www.biospace.com/article/releases/amarin-announces-vazkepa-icosapent-ethyl-approved-by-israel-s-ministry-of-health/